Trial Profile
A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Efgivanermin alfa (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Mesothelioma; Mouth neoplasm; Neuroendocrine tumours; Non-small cell lung cancer; Oropharyngeal cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 04 Sep 2020 Results published in the Clinical Cancer Research
- 07 Jan 2019 Status changed from active, no longer recruiting to completed.
- 30 Nov 2018 Planned End Date changed from 22 Jan 2021 to 7 Dec 2018.